Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. Summary
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
 SummaryQuotesChartsNewsRatingsCompanyFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
08/05/2022 08/08/2022 08/09/2022 08/10/2022 08/11/2022 Date
1.52 1.47 1.49 1.49 1.47 Last
1194881 3506859 2475121 840616 22276020 Volume
+2.70% -3.29% +1.36% 0.00% -1.34% Change
Company
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone... 
Read more
More about the company
Ratings of Epizyme, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about EPIZYME, INC.
2022Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
AQ
2022France's Ipsen Finalizes Purchase of US Biopharmaceutical Group Epizyme
MT
2022Epizyme, Inc. : Termination of a Material Definitive Agreement, Completion of Acquisition ..
AQ
2022Epizyme Announces Management Changes
CI
2022Epizyme, Inc. Appoints Grant Bogle as Chief Executive Officer
CI
2022Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Composite Index
CI
2022Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index
CI
2022Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P TMI Index
CI
2022Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Biotechnology In..
CI
2022Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. from RP Manag..
CI
2022Epizyme : Reports Second Quarter 2022 Financial Results and Provides Business Update - For..
PU
2022EPIZYME, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2022Epizyme : Q2 Earnings Snapshot
AQ
2022Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
BU
2022Earnings Flash (EPZM) EPIZYME Reports Q2 Revenue $27.5M
MT
More news
News in other languages on EPIZYME, INC.
2022Le français Ipsen finalise l'achat du groupe biopharmaceutique américain Epizyme
2022Epizyme annonce des changements de direction
2022Epizyme, Inc. nomme Grant Bogle au poste de directeur général
2022Ipsen a finalisé le rachat de la société américaine Epizyme spécialisée en oncologie
2022Ipsen Biopharmaceuticals, Inc. a finalisé l'acquisi..
More news
Analyst Recommendations on EPIZYME, INC.
More recommendations
Chart EPIZYME, INC.
Duration : Period :
Epizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Grant C. Bogle Chief Executive Officer
Christelle Huguet President
Jeffery L. Kutok Chief Scientific Officer & Executive VP
Jerald Korn Chief Operating Officer
François-Maurice Garnier Director
Sector and Competitors
1st jan.Capi. (M$)
EPIZYME, INC.-41.20%247
VERTEX PHARMACEUTICALS11.16%82 513
REGENERON PHARMACEUTICALS, INC.2.88%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008